STOCK TITAN

Voss Capital and Travis Cocke Hold 2.67M Shares of RNTX (11.3%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rein Therapeutics, Inc. receives a Schedule 13G/A disclosing that several Voss-related entities and Travis W. Cocke hold meaningful stakes in the company. The filing reports specific beneficial ownership amounts: Voss Value Master Fund holds 699,440 shares (3.0%), Voss Value-Oriented Special Situations Fund holds 316,768 shares (1.3%), Voss Advisors GP is attributable to 1,016,208 shares (4.3%), and Voss Capital and Travis W. Cocke are each reported as beneficial owners of 2,666,532 shares (11.3%). Those percentages are calculated against 23,547,429 shares outstanding as disclosed in the issuer’s registration statement. The cover pages show sole voting and dispositive power for the reported amounts and the filing includes a certification that the shares were not acquired to change or influence control of the issuer.

Positive

  • Voss Capital and Travis W. Cocke report a substantial stake (11.3%), a clearly disclosed and quantifiable minority position.
  • All reported shares show sole voting and dispositive power, providing transparent control lines for the holdings.
  • Ownership percentages are calculated against a clear outstanding share base (23,547,429 shares) disclosed in the issuer's registration statement.

Negative

  • Concentration of sole voting/dispositive power in Voss entities and Mr. Cocke could centralize shareholder influence.
  • Filing asserts the shares were not acquired to change control, which limits insight into potential future activist intentions.

Insights

TL;DR Voss-related entities and their manager report an 11.3% stake, a substantial minority position that could affect shareholder dynamics.

The disclosed 11.3% beneficial ownership by Voss Capital and Travis W. Cocke represents a material minority position relative to the reported 23.5 million shares outstanding. The filing shows sole voting and dispositive power over the reported shares, indicating direct control of voting rights rather than shared arrangements. The Schedule 13G/A classification and the signed certification state the holdings are not intended to change or influence control, which implies a passive reporting posture under the rules. For investors, the key measurable implications are concentration of voting power and clarity on construct of ownership—both are explicitly stated in the filing.

TL;DR A single manager and related funds are shown with concentrated, sole voting power over an 11.3% stake, raising governance visibility.

The filing attributes sole voting and dispositive authority to the reporting persons for their respective share blocks, and aggregates positions through the fund/manager structure to show an 11.3% beneficial ownership for Voss Capital and Mr. Cocke. That sole authority simplifies accountability for voting outcomes but concentrates influence in a small group. The statement’s explicit certification that the shares were not acquired to effect change in control clarifies intent, but does not alter the practical governance impact of a sizable, centrally controlled stake.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Voss Value Master Fund, LP
Signature:/s/ Travis W. Cocke
Name/Title:Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner
Date:09/26/2025
Voss Value-Oriented Special Situations Fund, LP
Signature:/s/ Travis W. Cocke
Name/Title:Travis W. Cocke, Managing Member of Voss Advisors GP, LLC, its General Partner
Date:09/26/2025
Voss Advisors GP, LLC
Signature:/s/ Travis W. Cocke
Name/Title:Travis W. Cocke, Managing Member
Date:09/26/2025
Voss Capital, LP
Signature:/s/ Travis W. Cocke
Name/Title:Travis W. Cocke, Managing Member
Date:09/26/2025
Cocke Travis W.
Signature:/s/ Travis W. Cocke
Name/Title:Travis W. Cocke
Date:09/26/2025

FAQ

How many shares of RNTX does Voss Capital report beneficially owning?

Voss Capital is reported as beneficially owning 2,666,532 shares, representing approximately 11.3% of the outstanding shares.

What percentage of Rein Therapeutics does Travis W. Cocke beneficially own?

Travis W. Cocke is reported as beneficially owning 2,666,532 shares, or about 11.3% of the class.

What is the total number of shares outstanding used to calculate percentages?

Percentages are based on 23,547,429 shares outstanding as disclosed in the issuer's registration statement.

Do the reporting persons claim they intend to influence control of Rein Therapeutics?

No. The filing contains a certification stating the securities were not acquired and are not held to change or influence control of the issuer.

Which Voss-related fund holds 699,440 shares of RNTX?

Voss Value Master Fund is reported as beneficially owning 699,440 shares, approximately 3.0% of the outstanding shares.

Are any reported holdings subject to shared voting or dispositive power?

No. The cover pages show zero shared voting power and zero shared dispositive power for the reported positions.
Rein Therapeutics, Inc.

NASDAQ:RNTX

RNTX Rankings

RNTX Latest News

RNTX Latest SEC Filings

RNTX Stock Data

31.81M
26.27M
0.09%
28.57%
0.12%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN